In this article, we first review a study showing that the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA glutamate receptor throughput in critical neuronal circuits. We hypothesize that ketamine directly mediates this throughput, whereas monoaminergic antidepressants work indirectly and gradually; this may explain, in part, the lag of onset of several weeks to months that is observed with traditional antidepressants.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
References and Recommended Reading
Fagiolini A, Kupfer DJ, Masalehdan A, et al.: Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005, 7:281–285.
Huxley N, Baldessarini RJ: Disability and its treatment in bipolar disorder patients. Bipolar Disord 2007, 9:183–196.
Rush AJ, Trivedi MH, Wisniewski SR, et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905–1917.
Trivedi MH, Rush AJ, Wisniewski SR, et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28–40.
Manji HK, Moore GJ, Rajkowska G, Chen G: Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000, 5:578–593.
Payne JL, Quiroz JA, Zarate CA, Jr, Manji HK: Timing is everything: does the robust upregulation of norad-renergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry 2002, 52:921–926.
Zarate CA, Jr, Singh J, Manji HK: Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006, 59:1006–1020.
Sanacora G, Rothman DL, Mason G, Krystal JH: Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 2003, 1003:292–308.
Zarate CA, Jr, Du J, Quiroz J, et al.: Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003, 1003:273–291.
Zarate CA, Quiroz J, Payne J, Manji HK: Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002, 36:35–83.
Krystal JH, D’souza DC, Petrakis IL, et al.: NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999, 7:125–143
Manji HK, Quiroz JA, Sporn J, et al.: Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53:707–742.
Malinow R, Malenka RC: AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 2002, 25:103–126.
Zhu JJ, Qin Y, Zhao M, et al.: Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 2002, 110:443–455.
Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH: Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982, 232:299–304.
Altamura CA, Mauri MC, Ferrara A, et al.: Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993, 150:1731–1733.
Mauri MC, Ferrara A, Boscati L, et al.: Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998, 37:124–129.
Mitani H, Shirayama Y, Yamada T, et al.: Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1155–1158.
Frye MA, Tsai GE, Huggins T, et al.: Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2007, 61:162–166.
Levine J, Panchalingam K, Rapoport A, et al.: Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000, 47:586–593.
Altamura C, Maes M, Dai J, Meltzer HY: Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995, 5(Suppl):71–75.
Maes M, Verkerk R, Vandoolaeghe E, et al.: Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998, 97:302–308.
Maj J, Rogoz Z, Skuza G, Sowinska H: The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. Neuropharmacology 1992, 31:685–691.
Meloni D, Gambarana C, De Montis MG, et al.: Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav 1993, 46:423–426.
Papp M, Moryl E: New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 1993, 45:549–553.
Skolnick P, Miller R, Young A, et al.: Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology (Berl) 1992, 107:489–496.
Trullas R, Folio T, Young A, et al.: 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 1991, 203:379–385.
Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990, 185:1–10.
Padovan CM, Guimaraes FS: Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol Biochem Behav 2004, 77:15–19.
Zarate CA, Jr, Payne JL, Quiroz J, et al.: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171–174.
Zarate CA, Jr, Quiroz JA, Singh JB, et al.: An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005, 57:430–432.
van Berckel BN, Lipsch C, Gispen-de Wied C, et al.: The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl) 1998, 138:190–197.
van Berckel BN, Lipsch C, Timp S, et al.: Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 1997, 16:317–324.
Lopes T, Neubauer P, Boje KM: Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacol Biochem Behav 1997, 58:1059–1064.
Papp M, Moryl E: Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 1996, 316:145–151.
Vamvakides A: D-cycloserine is active in the adult mouse and inactive in the aged mouse, in the forced swim test [in French]. Ann Pharm Fr 1998, 56:209–212.
Heresco-Levy U, Javitt DC, Gelfin Y, et al.: Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 2006, 93:239–243.
Reisberg B, Doody R, Stoffer A, et al.: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003, 348:1333–1341.
Zarate CA, Jr, Singh JB, Quiroz JA, et al.: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153–155.
Bolshakov KV, Gmiro VE, Tikhonov DB, Magazanik LG: Determinants of trapping block of N-methyl-d-aspartate receptor channels. J Neurochem 2003, 87:56–65.
Narita M, Yoshizawa K, Nomura M, et al.: Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine. Eur J Pharmacol 2001, 423:41–46.
De Vry J, Jentzsch KR: Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav Pharmacol 2003, 14:229–235.
Maler JM, Esselmann H, Wiltfang J, et al.: Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res 2005, 1052:156–162.
Green SM, Rothrock SG, Harris T, et al.: Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Acad Emerg Med 1998, 5:971–976.
Berman RM, Cappiello A, Anand A, et al.: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351–354.
Zarate CA, Jr, Singh JB, Carlson PJ, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856–864.
Entsuah AR, Huang H, Thase ME: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001, 62:869–877.
Thase ME, Haight BR, Richard N, et al.: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005, 66:974–981.
Wirz-Justice A, Van den Hoofdakker RH: Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 1999, 46:445–453.
Husain MM, Rush AJ, Fink M, et al.: Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004, 65:485–491.
Marangell LB, George MS, Callahan AM, et al.: Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997, 54:214–222.
DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF: Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebocontrolled study. Am J Psychiatry 2000, 157:1334–1337.
Krystal JH, Karper LP, Seibyl JP, et al.: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199–214.
Moghaddam B, Adams B, Verma A, Daly D: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921–2927.
Maeng S, Zarate CA, Jr, Du J, et al.: Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2007 [Epub ahead of print].
Du J, Suzuki K, Wei Y, et al.: The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007, 32:793–802.
Li X, Tizzano JP, Griffey K, et al.: Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028–1033.
Zarate CA, Jr, Charney DS, Manji HK: Searching for rational anti-N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry 2007, 64:1100–1101.
About this article
Cite this article
Maeng, S., Zarate, C.A. The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 9, 467–474 (2007). https://doi.org/10.1007/s11920-007-0063-1
- NMDA Receptor
- Mood Disorder